Bliss GVS Pharma Faces Mixed Financial Indicators Amid Profit Decline and Market Challenges
Bliss GVS Pharma has recently experienced a change in its evaluation, reflecting a shift in valuation metrics amid mixed financial indicators. The company faces challenges, including declining profits and negative growth in operating profit, while its stock shows a bearish trend, complicating its market position and financial health.
Bliss GVS Pharma, a small-cap player in the Pharmaceuticals & Drugs industry, has recently undergone an adjustment in evaluation that reflects a shift in its valuation metrics. The company’s financial indicators present a mixed picture, with a Price to Earnings (PE) ratio of 14.72 and a Price to Book Value of 1.23. Additionally, the company’s Enterprise Value to EBITDA stands at 8.81, while the Return on Capital Employed (ROCE) is reported at 13.60%.Despite these metrics, Bliss GVS Pharma has faced challenges, including a decline in profits over the past year and negative financial performance in recent quarters. The company has reported a decrease in Profit After Tax (PAT) and has shown a negative growth rate in operating profit over the last five years. Furthermore, the stock's technical indicators suggest a bearish trend, with various factors contributing to this outlook.
In light of these developments, the recent revision in its score highlights the complexities surrounding Bliss GVS Pharma's market position and financial health.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
